Evidence map›Paper›PMID 32913056›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane.

Que N Van, Cesar A López, Marco Tonelli, Troy Taylor, Ben Niu, Christopher B Stanley, Debsindhu Bhowmik, Timothy H Tran, Peter H Frank, Simon Messing and 19 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Nanodiscs for the study of membrane proteins.Current opinion in structural biology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Revealing KRas4b topology on the membrane surface.Biochemical and biophysical research communications · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 1 country.

Que N VanNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-2919-7375
Cesar A LópezTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0003-4684-3364
Marco TonelliNational Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.ORCID 0000-0002-7700-5745
Troy TaylorNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0001-6775-629X
Ben NiuNational Mass Spectrometry Resource, Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130.ORCID 0000-0002-6646-9085
Christopher B StanleyComputational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831.ORCID 0000-0002-4226-7710
Debsindhu BhowmikComputational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831.ORCID 0000-0001-7770-9091
Timothy H TranNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0003-1342-7620
Peter H FrankNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0001-8085-7845
Simon MessingNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0001-8991-2097
Patrick AlexanderNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0001-8601-1760
Daniel ScottDepartment of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213.ORCID 0000-0003-0351-6494
Xiaoying YeNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-5659-8270
Matt DrewNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-3954-6671
Oleg ChertovNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-0426-2521
Mathias LöscheDepartment of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213.ORCID 0000-0001-6666-916X
Arvind RamanathanData Science and Learning Division, Argonne National Laboratory, Lemont, IL 60439.ORCID 0000-0002-1622-5488
Michael L GrossNational Mass Spectrometry Resource, Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130.ORCID 0000-0003-1159-4636
Nicolas W HengartnerTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-4157-134X
William M WestlerNational Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.ORCID 0000-0003-2799-671X
John L MarkleyNational Magnetic Resonance Facility at Madison, Biochemistry Department, University of Wisconsin-Madison, Madison, WI 53706.ORCID 0000-0003-1799-6134
Dhirendra K SimanshuNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-9717-4618
Dwight V NissleyNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0001-7523-116X
William K GilletteNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-8592-3642
Dominic EspositoNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702.ORCID 0000-0002-9987-1687
Frank McCormickNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702; frank.mccormick@ucsf.edu stephena@mail.nih.gov.ORCID 0000-0002-6619-7120
S GnanakaranTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-9368-3044
Frank HeinrichDepartment of Physics, Carnegie Mellon University, Pittsburgh, PA 15213.ORCID 0000-0002-8579-553X
Andrew G StephenNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702; frank.mccormick@ucsf.edu stephena@mail.nih.gov.ORCID 0000-0002-8259-621X
Leidos (United States) · USLos Alamos National Laboratory · USUniversity of Wisconsin–Madison · USNational Institute of Standards and Technology · USOak Ridge National Laboratory · USWashington University in St. Louis · USArgonne National Laboratory · USCarnegie Mellon University · US

Funding

UNM TRAININGP50GM085273 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI EDWARDS, JEREMY S · 2009 to 2018
$26.1M
TrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0M
TR&D 3: TECHNOLOGY DEVELOPMENT FOR NMR STUDIES OF SMALL MOLECULES (METABOLOMICS, NATURAL PRODUCTS, METABOLITE-PROTEIN INTERACTIONS) pp.537-585 P41GM103399 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2012 to 2019
$9.4M
A Large-area Pixel Array Detector System for Macromolecular CrystallographyS10RR028438 · NCRR · STANFORD UNIVERSITY · PI WEIS, WILLIAM I · 2010 to 2010
$2.1M
Integrated state-of-the-art LC-MS/NMR system for the University of WisconsinS10RR025062 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2008 to 2008
$1.7M
Upgrade of the NMRFAM 750 MHz NMR SpectrometerS10RR029220 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2010 to 2010
$766k
NMR Spectrometer System Optimized for Direct 13C or 15N DetectionS10RR023438 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2008 to 2008
$500k
CONSOLE UPGRADES FOR NMR FACILITYS10RR008438 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI MARKLEY, JOHN L · 1993 to 1993
–
WIDE-BORE 9.4 TESLA NMR SPECTROMETER FOR UW-MADISONS10RR002781 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI MARKLEY, JOHN L · 1986 to 1986
–
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCRR NIH HHS S10 RR002781NCRR NIH HHS S10 RR008438NCRR NIH HHS S10 RR023438NCRR NIH HHS S10 RR025062NCRR NIH HHS S10 RR028438NCRR NIH HHS S10 RR029220NIGMS NIH HHS P41 GM103399NIGMS NIH HHS P41 GM103422NIGMS NIH HHS P50 GM085273
6 · The paper itself

Abstract

The small GTPase KRAS is localized at the plasma membrane where it functions as a molecular switch, coupling extracellular growth factor stimulation to intracellular signaling networks. In this process, KRAS recruits effectors, such as RAF kinase, to the plasma membrane where they are activated by a series of complex molecular steps. Defining the membrane-bound state of KRAS is fundamental to understanding the activation of RAF kinase and in evaluating novel therapeutic opportunities for the inhibition of oncogenic KRAS-mediated signaling. We combined multiple biophysical measurements and computational methodologies to generate a consensus model for authentically processed, membrane-anchored KRAS. In contrast to the two membrane-proximal conformations previously reported, we identify a third significantly populated state using a combination of neutron reflectivity, fast photochemical oxidation of proteins (FPOP), and NMR. In this highly populated state, which we refer to as "membrane-distal" and estimate to comprise ∼90% of the ensemble, the G-domain does not directly contact the membrane but is tethered via its C-terminal hypervariable region and carboxymethylated farnesyl moiety, as shown by FPOP. Subsequent interaction of the RAF1 RAS binding domain with KRAS does not significantly change G-domain configurations on the membrane but affects their relative populations. Overall, our results are consistent with a directional fly-casting mechanism for KRAS, in which the membrane-distal state of the G-domain can effectively recruit RAF kinase from the cytoplasm for activation at the membrane.

Indexed as

Cell MembraneMolecular Dynamics SimulationProto-Oncogene Proteins p21(ras)raf KinasesKRAS protein, humanProto-Oncogene Proteins p21(ras)raf KinasesKRASmembraneneutron reflectometrynuclear magnetic resonanceRAF RBD

Identifiers

PMID32913056
PMCPMC7533834
OpenAlexW3086643546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.